Rezolute Announces Q1 EPS of 18 Cents, Below Consensus Estimate of 26 Cents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Phase 3 Trial Updates: Rezolute is on track to report topline results from the Phase 3 sunRIZE trial for congenital hyperinsulinism in December.
Tumor Hyperinsulinism Trial: Enrollment for the streamlined Phase 3 trial in tumor hyperinsulinism is underway, with topline data expected in the second half of next year.
Commercialization Plans: The company is advancing towards potential commercialization of ersodetug for hyperinsulinism treatment.
Investor Event: Rezolute plans to highlight its progress at an upcoming investor event next week.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RZLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 6.29 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.250
Low
2.00
Averages
6.29
High
20.00
Current: 3.250
Low
2.00
Averages
6.29
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Investor Losses in Rezolute
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc., aiming to provide legal support for investors who have suffered significant losses, highlighting the legal risks the company may face.
- Investor Rights Advocacy: The firm encourages investors who have incurred losses in Rezolute stock or options to contact partner Josh Wilson directly, demonstrating its commitment to protecting investor rights and actively advocating for their interests.
- Historical Performance Review: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its strong capabilities and extensive experience in securities law, which enhances investor trust in its services.
- Contact Information Provided: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310), offering a convenient communication channel for affected investors seeking legal assistance.
Continue Reading
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options
- Legal Consultation Advocacy: Faruq & Faruqi's Securities Litigation Partner Josh Wilson encourages investors who have suffered significant losses in Rezolute stock or options to contact him directly, highlighting the firm's commitment to investor rights.
- Potential Claims Investigation: The firm is investigating potential claims against Rezolute, Inc., indicating that the company may face legal risks, which investors should monitor to protect their interests.
- Investor Loss Focus: Faruq & Faruqi emphasizes that investors who have incurred significant losses in Rezolute should seek legal advice promptly, reflecting a proactive approach to investor protection and potential compensation.
- Firm Background Overview: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, thereby enhancing investor trust in its services.
Continue Reading